1. Home
  2. EARN vs CMPX Comparison

EARN vs CMPX Comparison

Compare EARN & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EARN
  • CMPX
  • Stock Information
  • Founded
  • EARN 2012
  • CMPX 2014
  • Country
  • EARN United States
  • CMPX United States
  • Employees
  • EARN N/A
  • CMPX N/A
  • Industry
  • EARN Real Estate Investment Trusts
  • CMPX Biotechnology: Pharmaceutical Preparations
  • Sector
  • EARN Real Estate
  • CMPX Health Care
  • Exchange
  • EARN Nasdaq
  • CMPX Nasdaq
  • Market Cap
  • EARN 189.7M
  • CMPX 730.9M
  • IPO Year
  • EARN 2013
  • CMPX N/A
  • Fundamental
  • Price
  • EARN $5.14
  • CMPX $4.22
  • Analyst Decision
  • EARN Buy
  • CMPX Strong Buy
  • Analyst Count
  • EARN 2
  • CMPX 7
  • Target Price
  • EARN $5.88
  • CMPX $14.71
  • AVG Volume (30 Days)
  • EARN 350.1K
  • CMPX 1.7M
  • Earning Date
  • EARN 11-11-2025
  • CMPX 11-11-2025
  • Dividend Yield
  • EARN 18.68%
  • CMPX N/A
  • EPS Growth
  • EARN N/A
  • CMPX N/A
  • EPS
  • EARN N/A
  • CMPX N/A
  • Revenue
  • EARN $35,893,000.00
  • CMPX N/A
  • Revenue This Year
  • EARN N/A
  • CMPX N/A
  • Revenue Next Year
  • EARN $15.96
  • CMPX N/A
  • P/E Ratio
  • EARN N/A
  • CMPX N/A
  • Revenue Growth
  • EARN 43.30
  • CMPX N/A
  • 52 Week Low
  • EARN $4.33
  • CMPX $1.27
  • 52 Week High
  • EARN $7.11
  • CMPX $4.86
  • Technical
  • Relative Strength Index (RSI)
  • EARN 34.05
  • CMPX 58.74
  • Support Level
  • EARN $5.01
  • CMPX $3.31
  • Resistance Level
  • EARN $5.20
  • CMPX $4.86
  • Average True Range (ATR)
  • EARN 0.12
  • CMPX 0.29
  • MACD
  • EARN -0.01
  • CMPX 0.06
  • Stochastic Oscillator
  • EARN 21.51
  • CMPX 58.36

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

Share on Social Networks: